Published in Blood Rev on January 01, 2010
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer (2010) 1.97
Characterization of chronic myeloid leukemia stem cells. Am J Hematol (2011) 1.15
CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood (2014) 1.09
Targeted therapy in Ewing sarcoma. ISRN Oncol (2012) 0.78
Chronic myeloid leukemia: the basis of treatment for tomorrow. Haematologica (2011) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 6.64
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood (2006) 4.41
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell (2012) 2.96
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood (2007) 2.68
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood (2011) 2.11
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell (2012) 2.08
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood (2006) 1.85
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst (2013) 1.75
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood (2002) 1.68
Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. Blood (2013) 1.65
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood (2007) 1.60
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica (2009) 1.50
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood (2006) 1.43
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood (2007) 1.40
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood (2010) 1.33
Punish the parent not the progeny. Blood (2004) 1.32
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res (2008) 1.30
Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res (2006) 1.29
Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells (2007) 1.24
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood (2012) 1.16
Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood (2011) 1.16
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood (2013) 1.13
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells (2014) 1.13
Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol (2007) 1.09
Evolving molecular therapy for chronic myeloid leukaemia--are we on target? Hematology (2005) 1.04
Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny. PLoS One (2012) 1.01
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica (2011) 1.00
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood (2012) 0.99
Autophagy in blood cancers: biological role and therapeutic implications. Haematologica (2013) 0.99
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood (2013) 0.98
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells (2007) 0.97
Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. Stem Cells (2014) 0.96
Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance. Blood (2013) 0.95
In search of CML stem cells' deadly weakness. Curr Hematol Malig Rep (2011) 0.94
Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. PLoS One (2011) 0.91
A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health (2009) 0.91
Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. Cancer Res (2010) 0.88
Targeting chronic myeloid leukemia stem cells. Curr Hematol Malig Rep (2010) 0.88
Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Rev Anticancer Ther (2012) 0.87
HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis (2006) 0.87
Role of autophagy in cancer prevention, development and therapy. Essays Biochem (2013) 0.86
Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol (2009) 0.86
Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. Blood (2008) 0.86
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol Biotechnol (2007) 0.86
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Br J Haematol (2012) 0.85
Uptake of synthetic Low Density Lipoprotein by leukemic stem cells--a potential stem cell targeted drug delivery strategy. J Control Release (2010) 0.84
Retracted FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. Blood (2009) 0.84
Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. J Exp Med (2011) 0.83
Hurdles toward a cure for CML: the CML stem cell. Hematol Oncol Clin North Am (2011) 0.83
Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Exp Hematol (2005) 0.82
Targeted therapy in haematological malignancies. J Pathol (2010) 0.82
Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol (2010) 0.82
Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients. Proteomics (2013) 0.81
Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. Exp Hematol (2008) 0.80
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol (2003) 0.80
Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets (2013) 0.80
Stem cells in chronic myeloid leukaemia. Cancer Biomark (2007) 0.80
Redirecting traffic using the XPO1 police. Blood (2013) 0.80
Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer (2005) 0.79
Can we afford to let sleeping dogs lie? Blood (2005) 0.79
A specific PTPRC/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility. Mol Cell Proteomics (2013) 0.79
Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. Br J Haematol (2005) 0.79
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. Blood (2012) 0.78
Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J Clin Invest (2014) 0.77
Predictive response-relevant clustering of expression data provides insights into disease processes. Nucleic Acids Res (2010) 0.77
Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon? Expert Rev Hematol (2011) 0.77
Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Exp Hematol (2009) 0.77
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol (2013) 0.76
Published rather than proposed definitions for invasive fungal infection must be applied to allow standardization in clinical trials. Clin Infect Dis (2004) 0.75
Isolation and therapeutic potential of human haemopoietic stem cells. Cytotechnology (2003) 0.75
High loading dose AmBisome is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. Haematologica (2007) 0.75
Investigation into omacetaxine solution stability for in vitro study. Biomed Chromatogr (2011) 0.75
Fluorescence in situ hybridization for BCR-ABL. Methods Mol Med (2004) 0.75
BCR-ABL FISH monitoring of CML: a survey of current UK practice. Br J Haematol (2002) 0.75
Stem Cell Guardians - Old and New Perspectives in LSC Biology. Curr Drug Targets (2017) 0.75